Nifty
Sensex
:
:
8412.80
27288.17
12.45(0.15%)
50.11(0.18%)

Pharmaceuticals & Drugs

Rating :
71/99   (View)

BSE: 532523 | NSE: BIOCON

997.95
3.50 (0.35%)
16-Jan-2017 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 994.90
  • 1012.00
  • 980.00
  • 994.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 614001
  • 6127.42
  • 1051.75
  • 431.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 19,887.00
  • 25.59
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 20,443.40
  • 0.50%
  • 4.50

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.68%
  • 1.19%
  • 12.45%
  • FII
  • DII
  • Others
  • 1.3%
  • 3.77%
  • 20.61%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 16
Sep 15
Var%
Jun 16
Jun 15
Var%
Mar 16
Mar 15
Var%
Dec 15
Dec 14
Var%
Net Sales
945.80
837.20
12.97%
982.40
832.99
17.94%
978.80
837.68
16.85%
836.40
769.22
8.73%
Expenses
705.80
639.54
10.36%
719.30
620.81
15.86%
765.70
652.45
17.36%
647.30
609.27
6.24%
EBITDA
240.00
197.66
21.42%
263.10
212.18
24.00%
213.10
185.23
15.05%
189.10
159.95
18.22%
EBIDTM
25.15%
23.61%
26.78%
25.47%
21.77%
22.11%
22.61%
20.79%
Other Income
38.40
24.60
56.10%
40.90
23.52
73.89%
24.70
16.83
46.76%
19.70
9.77
101.64%
Interest
6.50
2.93
121.84%
5.70
4.42
28.96%
1.40
0.00
0.00
1.50
4.79
-68.68%
Depreciation
68.30
59.61
14.58%
66.10
57.80
14.36%
62.80
58.52
7.31%
62.10
56.30
10.30%
PBT
203.60
466.72
-56.38%
232.20
173.48
33.85%
442.00
248.60
77.80%
145.20
108.63
33.66%
Tax
41.70
137.69
-69.71%
55.20
36.95
49.39%
58.20
31.80
83.02%
24.10
11.15
116.14%
PAT
161.90
329.03
-50.79%
177.00
136.53
29.64%
383.80
216.80
77.03%
121.10
97.48
24.23%
PATM
16.97%
39.30%
18.02%
16.39%
39.21%
25.88%
14.48%
12.67%
EPS
7.34
15.30
-52.03%
8.33
6.31
32.01%
18.05
10.08
79.07%
5.15
4.55
13.19%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Net Sales
3,485.40
3,089.80
2,877.30
2,485.30
2,086.50
1,806.00
2,367.82
1,608.67
1,053.79
985.73
Net Sales Growth
12.80%
7.39%
15.77%
19.11%
15.53%
-23.73%
47.19%
52.66%
6.90%
 
Cost Of Goods Sold
1,329.90
1,255.60
1,186.10
1,044.40
852.00
725.40
1,337.54
838.42
434.62
450.78
Gross Profit
2,155.50
1,834.20
1,691.20
1,440.90
1,234.50
1,080.60
1,030.27
770.25
619.17
534.96
GP Margin
61.84%
59.36%
58.78%
57.98%
59.17%
59.83%
43.51%
47.88%
58.76%
54.27%
Total Expenditure
2,670.10
2,394.00
2,190.20
1,946.30
1,809.30
2,213.40
1,896.33
1,285.31
757.67
712.01
Power & Fuel Cost
194.20
176.70
162.40
142.60
97.20
82.00
67.63
69.33
76.56
61.96
% Of Sales
5.57%
5.72%
5.64%
5.74%
4.66%
4.54%
2.86%
4.31%
7.27%
6.29%
Employee Cost
636.30
533.40
466.30
389.40
307.60
238.80
242.76
179.18
110.68
89.17
% Of Sales
18.26%
17.26%
16.21%
15.67%
14.74%
13.22%
10.25%
11.14%
10.50%
9.05%
Manufacturing Exp.
175.00
81.20
62.90
95.20
113.20
81.60
68.63
66.01
47.71
41.32
% Of Sales
5.02%
2.63%
2.19%
3.83%
5.43%
4.52%
2.90%
4.10%
4.53%
4.19%
General & Admin Exp.
151.50
165.70
131.80
122.20
93.20
82.40
79.09
56.15
38.71
33.18
% Of Sales
4.35%
5.36%
4.58%
4.92%
4.47%
4.56%
3.34%
3.49%
3.67%
3.37%
Selling & Distn. Exp.
113.90
108.70
118.90
99.60
89.40
62.40
56.49
47.67
32.53
23.34
% Of Sales
3.27%
3.52%
4.13%
4.01%
4.28%
3.46%
2.39%
2.96%
3.09%
2.37%
Miscellaneous Exp.
69.30
72.70
61.80
52.90
256.70
940.80
44.19
28.55
16.84
23.34
% Of Sales
1.99%
2.35%
2.15%
2.13%
12.30%
52.09%
1.87%
1.77%
1.60%
1.24%
EBITDA
815.30
695.80
687.10
539.00
277.20
-407.40
471.49
323.36
296.12
273.72
EBITDA Margin
23.39%
22.52%
23.88%
21.69%
13.29%
-22.56%
19.91%
20.10%
28.10%
27.77%
Other Income
89.20
53.10
55.90
56.70
309.40
1,035.50
37.02
64.55
38.88
13.70
Interest
10.20
8.90
1.70
8.10
12.40
24.30
16.89
17.66
10.18
9.88
Depreciation
242.30
221.00
203.60
179.30
175.80
156.70
140.14
110.25
93.92
66.55
PBT
652.00
519.00
537.70
408.30
398.40
447.10
351.47
260.00
230.91
211.00
Tax
256.90
95.70
106.90
97.50
55.90
72.10
48.67
11.84
12.89
16.91
Tax Rate
20.93%
15.33%
19.88%
15.98%
14.03%
16.13%
13.85%
10.50%
2.74%
8.01%
PAT
896.10
497.40
413.80
508.90
341.60
367.50
293.25
93.84
463.91
200.26
PAT before Minority Interest
970.50
528.40
430.80
512.70
342.50
375.00
302.81
100.97
457.39
194.08
Minority Interest
-74.40
-31.00
-17.00
-3.80
-0.90
-7.50
-9.56
-7.13
6.52
6.18
PAT Margin
25.71%
16.10%
14.38%
20.48%
16.37%
20.35%
12.38%
5.83%
44.02%
20.32%
PAT Growth
80.16%
20.20%
-18.69%
48.98%
-7.05%
25.32%
212.50%
-79.77%
131.65%
 
Unadjusted EPS
44.81
24.87
21.09
25.99
17.27
18.79
15.08
4.83
46.39
21.47

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Shareholder's Funds
4,055.60
3,270.60
3,026.70
2,694.60
2,272.40
2,032.80
1,757.85
1,510.74
1,484.15
1,068.61
Share Capital
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
50.00
50.00
Total Reserves
3,904.80
3,132.70
2,806.20
2,491.80
2,079.80
1,850.50
1,595.96
1,369.32
1,397.80
992.55
Non-Current Liabilities
2,487.20
1,377.90
1,262.00
666.30
645.20
455.50
564.44
570.54
301.55
231.60
Secured Loans
2,068.50
758.20
580.40
124.00
9.30
0.00
331.50
395.73
135.04
73.73
Unsecured Loans
3.90
11.40
25.80
40.00
60.50
65.80
182.11
128.18
120.01
113.04
Long Term Provisions
29.90
15.00
7.80
4.00
0.00
1.00
0.00
0.00
0.00
0.00
Current Liabilities
1,627.60
1,554.70
1,379.60
989.90
1,015.80
1,060.60
581.73
438.50
301.42
274.98
Trade Payables
547.10
429.30
347.20
345.50
347.80
296.50
230.86
208.55
172.38
193.70
Other Current Liabilities
597.90
706.20
612.30
313.10
269.20
375.90
260.05
148.42
57.64
38.73
Short Term Borrowings
394.90
261.00
243.50
84.80
187.30
247.40
0.00
0.00
0.00
0.00
Short Term Provisions
87.70
158.20
176.60
246.50
211.50
140.80
90.83
81.53
71.40
42.56
Total Liabilities
8,481.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.80
1,574.39
Net Block
1,722.60
1,629.90
1,525.20
1,510.30
1,270.50
1,316.20
1,337.93
1,211.56
931.28
894.90
Gross Block
3,373.00
3,034.20
2,701.70
2,480.90
2,066.20
1,965.80
1,837.13
1,581.70
1,182.39
1,066.11
Accumulated Depreciation
1,650.40
1,404.30
1,176.50
970.60
795.70
649.60
499.20
370.14
251.11
171.21
Non Current Assets
4,488.40
3,812.80
3,111.80
2,176.10
1,937.50
1,779.40
1,460.60
1,422.68
1,101.10
983.50
Capital Work in Progress
2,187.50
1,676.40
1,205.60
312.50
389.50
262.10
75.52
172.02
138.21
70.83
Non Current Investment
0.00
0.00
64.50
64.50
64.20
60.90
47.16
39.10
31.60
17.77
Long Term Loans & Adv.
381.00
336.90
252.00
241.60
181.00
140.20
0.00
0.00
0.00
0.00
Other Non Current Assets
197.30
169.60
64.50
47.20
32.30
0.00
0.00
0.00
0.00
0.00
Current Assets
3,993.20
2,562.60
2,638.80
2,240.00
1,999.70
1,807.20
1,477.21
1,121.87
978.71
590.90
Current Investments
428.50
230.30
700.40
522.10
492.10
399.50
383.42
328.52
443.16
61.31
Inventories
511.40
452.70
376.60
398.40
378.30
413.70
371.64
319.18
178.98
161.32
Sundry Debtors
822.90
770.50
599.80
509.70
491.70
495.80
446.13
366.68
259.13
306.52
Cash & Bank
1,921.30
937.50
804.40
672.90
523.30
441.50
139.93
11.81
9.62
8.73
Other Current Assets
309.10
171.60
157.60
136.90
114.30
56.70
136.10
95.67
87.82
53.01
Short Term Loans & Adv.
185.30
75.80
81.80
81.40
37.10
20.20
120.28
95.05
82.76
51.58
Net Current Assets
2,365.60
1,007.90
1,259.20
1,250.10
983.90
746.60
895.48
683.37
677.28
315.91
Total Assets
8,481.60
6,375.40
5,750.60
4,416.10
3,937.20
3,586.60
2,937.81
2,544.55
2,079.81
1,574.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
526.40
210.70
560.70
471.20
564.10
798.50
443.81
95.10
317.91
154.76
PBT
1,227.40
624.10
537.70
610.20
395.20
447.10
351.47
104.36
538.66
211.00
Adjustment
-409.40
74.00
134.00
147.30
144.80
163.50
159.65
135.89
-213.83
82.18
Changes in Working Capital
-44.80
-354.00
37.70
-192.30
98.00
269.20
-34.53
-128.21
17.34
-125.19
Cash after chg. in Working capital
773.20
344.10
709.40
565.20
638.00
879.80
476.60
112.04
342.18
167.99
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-246.80
-133.40
-148.70
-94.00
-73.90
-81.30
-32.79
-16.94
-24.27
-13.24
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-954.00
-508.70
-938.10
-375.80
-359.50
-314.50
-226.07
-232.19
-340.15
-191.17
Net Fixed Assets
-270.30
-57.90
-322.80
-213.80
-75.20
-134.97
-55.73
-84.56
-53.65
-118.55
Net Investments
-446.10
328.50
125.80
38.00
-171.10
-67.26
-71.95
130.57
-430.24
92.04
Others
-237.60
-779.30
-741.10
-200.00
-113.20
-112.27
-98.39
-278.20
143.74
-164.66
Cash from Financing Activity
1,086.70
186.20
426.00
-8.60
-186.30
-274.60
-85.21
136.93
23.22
43.09
Net Cash Inflow / Outflow
659.10
-111.80
48.60
86.80
18.30
209.40
132.53
-0.16
0.99
6.68
Opening Cash & Equivalents
462.60
557.00
474.00
369.00
359.00
139.90
11.81
9.62
8.63
1.95
Closing Cash & Equivalent
1,127.00
462.60
557.00
474.00
369.00
359.00
143.10
11.81
9.62
8.63

Financial Ratios

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Book Value (Rs.)
200.19
161.59
145.26
129.54
108.94
97.48
84.75
73.42
72.34
52.07
ROA
13.06%
8.72%
8.47%
12.28%
9.10%
11.50%
11.05%
4.37%
25.03%
13.56%
ROE
26.83%
17.22%
15.68%
21.50%
16.59%
20.58%
19.14%
6.93%
36.76%
20.24%
ROCE
22.67%
15.30%
15.75%
22.47%
16.74%
20.33%
17.12%
6.92%
32.11%
19.67%
Fixed Asset Turnover
1.10
1.09
1.12
1.11
1.06
0.97
1.42
1.19
0.96
1.39
Receivable days
82.64
80.09
69.48
72.22
84.37
93.20
60.98
69.27
95.54
94.69
Inventory Days
50.00
48.47
48.54
56.01
67.67
77.71
51.83
55.14
57.48
48.54
Payable days
65.85
58.15
55.73
65.24
70.25
70.62
41.52
51.80
83.01
95.35
Cash Conversion Cycle
66.79
70.42
62.29
62.99
81.79
100.29
71.30
72.61
70.02
47.88
Total Debt/Equity
0.62
0.35
0.30
0.10
0.12
0.17
0.30
0.36
0.18
0.18
Interest Cover
121.33
71.12
317.29
76.33
33.13
19.40
21.81
7.39
47.20
22.37

News Update


  • Biocon's Novel Diabetes Education Initiative for Medical Practitioners 'ABIDE' Awarded by RSSDI
    29th November 2016

    ABIDE is a 'paradigm-shifting' initiative designed to empower primary care physicians who treat diabetes on a regular basis

    Read More
  • Biocon collaborates with healthcare specialists to mark 'World Diabetes Day'
    14th November 2016

    Through this month-long initiative being delivered in collaboration with 400 healthcare specialists in over 85 cities across the country and the company is targeting to reach out to over 50,000 people

    Read More
  • EMA to review Biocon-Mylan’s version of Glargine insulin
    4th November 2016

    Glargine is a long-acting insulin analog used to treat adults with type 2 diabetes

    Read More
  • Biocon features among world’s Top Ten Employers in Biotechnology
    29th October 2016

    The company has moved up to No 9 in ‘Science 2016 Top Employer’ ranking from No 13 last year

    Read More
  • Biocon reports consolidated net profit of Rs 146.7 crore in Q2
    21st October 2016

    Total income of the company has increased by 21.20% at Rs 992.50 crore for quarter under review

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.